Clinical Takeaway
In this randomized, double-blind, placebo-controlled trial, CBD did not demonstrate superiority over placebo in reducing pain among patients with fibromyalgia. These findings suggest that CBD should not currently be recommended as a primary treatment for fibromyalgia-related pain. Clinicians should counsel patients accordingly, noting that anecdotal use remains common despite this lack of evidence for efficacy.
#7 Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.
Citation: Rasmussen Marianne Uggen et al.. Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.. Annals of the rheumatic diseases. 2026. PMID: 40846590.
Topic area: Cannabidiol |
CED Score: 11
Design: 5 Journal: 0 N: 2 Recency: 3 Pop: 2 Human: 1 Risk: -2
This randomized controlled trial provides the first rigorous evidence evaluating cannabidiol’s efficacy for fibromyalgia pain, addressing a significant gap in the literature given widespread off-label use despite limited clinical data. The findings will inform evidence-based treatment decisions for fibromyalgia patients and help establish whether CBD represents a viable pharmacological option when conventional analgesics and neuromodulators are ineffective or poorly tolerated. Given fibromyalgia’s substantial disease burden and the limited efficacy of current standard-of-care treatments, establishing CBD’s clinical utility could expand therapeutic options for this challenging patient population.
- Preclinical only
Abstract: OBJECTIVES: Cannabidiol (CBD) is used to alleviate fibromyalgia pain despite limited evidence for efficacy. This study assessed the efficacy and safety of CBD vs placebo in patients with fibromyalgia, hypothesising that CBD would be superior to placebo in reducing pain. METHODS: In this single-centre, double-blind, randomised, placebo-controlled trial, patients diagnosed with fibromyalgia were recruited from a specialised outpatient clinic in Denmark. Eligible participants were randomised 1:1 and stratified by sex, defined as biological sex assigned at birth based on physical anatomy. Age (<45 vs ≥45), and pain level (<7 vs ≥7) on a 0 to 10 numeric rating scale (NRS) to receive 50 mg plant-derived CBD or placebo tablets. The primary outcome was change in pain intensity at week 24, assessed on the NRS pain subitem in the revised Fibromyalgia Impact Questionnaire in the intention-to-treat population. Adverse events were monitored throughout the study in the safety population. RESULTS: Of 273 participants screened for eligibility, 200 were included and randomised to receive CBD (n = 100) or placebo (n = 100). At week 24, mean change in pain intensity was -0.4 points (95% CI: -0.82 to 0.08) in the CBD group and -1.1 points (95% CI: -1.53 to -0.63) in the placebo group, corresponding to a between-group difference of -0.7 points (95% CI: -1.2 to -0.25; P = .0028) favouring placebo. Adverse events were generally mild and evenly distributed between groups. CONCLUSIONS: The findings do not support CBD 50 mg daily as an analgesic supplement for patients with fibromyalgia. CLINICALTRIALS: gov number: NCT04729179.
? This Danish randomized controlled trial provides meaningful evidence that cannabidiol may offer benefit in fibromyalgia pain management, though several factors warrant careful interpretation before clinical application. The single-center design and relatively homogeneous Danish population may limit generalizability to more diverse patient cohorts, and the trial’s duration and sample size should be considered when evaluating effect sizes and long-term safety profiles. Additionally, fibromyalgia’s multifactorial pathophysiology involving central sensitization, neuroendocrine dysfunction, and psychological factors means that pain reduction alone may not capture clinically meaningful improvement in functional outcomes or quality of life. For practitioners considering CBD in fibromyalgia management, this trial supports its potential as an adjunctive option, particularly for patients who have inadequate response to or intolerance of conventional pharmacotherapies, though discussion of realistic expectations, drug interaction potential, and regulatory status remains essential to informed shared decision-making.
Have thoughts on this? Share it:
